Prostate Cancer
The Journey of Antibody-Drug Conjugates: Lessons Learned from 40 Years of Development
October 30, 2024
Pelvic Lymph Node Dissection in Prostate Cancer: Update from a Randomized Clinical Trial of Limited Versus Extended Dissection.
October 30, 2024
AI-derived Tumor Volume from Multiparametric MRI and Outcomes in Localized Prostate Cancer.
October 30, 2024
Practice patterns and predictors of treatment intensification in patients with metastatic castration-sensitive prostate cancer.
October 30, 2024
Germline DNA damage repair variants and prognosis of patients with high-risk or metastatic prostate cancer.
October 30, 2024
Radical Prostatectomy or Watchful Waiting in Early Prostate Cancer.
October 30, 2024
Safety and Efficacy of Neoadjuvant Docetaxel and Radiotherapy in Localized High-Risk Prostate Cancer: Results From a Prospective Pilot Study.
October 30, 2024
What's in a Name? Why Words Matter in Advanced Prostate Cancer.
October 30, 2024
Low SMARCD3 expression is associated with poor prognosis in patients with prostate cancer.
October 29, 2024
Trends in Age and Prostate-Specific Antigen at Prostate Cancer Diagnosis between 2010 and 2019.
October 29, 2024
Postprostatectomy Radiotherapy Timing and Long-Term Health-Related Quality of Life.
October 28, 2024
Prostate Cancer Risk Stratification in NRG Oncology Phase III Randomized Trials Using Multimodal Deep Learning With Digital Histopathology.
October 28, 2024